Novo Nordisk A/S
Copenhagen : NOVO B

November 07, 2011 09:51 ET

Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes

BAGSVAERD, DENMARK--(Marketwire - Nov 7, 2011) -

Company Announcement no 70 / 2011:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Contact Information